Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma

Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma

Prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma is characterized by repeated cycles of remission followed by symptom recurrence, persistent detection of SARS-CoV-2, and profound humoral immunodeficiency. To the best of our knowledge, the present report is the first...

Full description

Bibliographic Details
Main Authors:	Seowoong Jung, Yu Yagi, Kazuaki Fukushima, Yukari Nishikawa, Masaru Tanaka, Taiichiro Kobayashi, Keishiro Yajima, Atsushi Ajisawa, Akifumi Imamura
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Series:	IDCases
Subjects:	Prolonged COVID-19 B-cell depleting immunotherapy Remdesivir Ensitrelvir Dual antiviral therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214250923002147

Similar Items

Letter to the Editor: “Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19”
by: Hideharu Hagiya
Published: (2024-09-01)

Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor
by: Takayuki Katsube, et al.
Published: (2024-03-01)

Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19
by: Takahiro Takazono, et al.
Published: (2024-06-01)

Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge
by: Seki M, et al.
Published: (2024-11-01)

Letter to the Editor regarding Response to “Letter to Editor: “Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19”
by: Takahiro Takazono, et al.
Published: (2024-09-01)

A case report on the association between QTc prolongation and remdesivir therapy in a critically ill patient
by: Shmeylan Al Harbi, et al.
Published: (2022-01-01)

Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series
by: Hanako Naganawa, et al.
Published: (2024-07-01)

Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan
by: Akihiro Doi, et al.
Published: (2024-06-01)

Modeling the Impact of Ensitrelvir on SARS-CoV-2 Dynamics and Its Application for Assessment of Transmission Mitigation of Patients with COVID-19
by: Daichi Yamaguchi, et al.
Published: (2024-10-01)

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistanceResearch in context
by: Jonathan Daniel Ip, et al.
Published: (2023-05-01)

Investigating the effects of remdesivir on corrected QT interval in patients with severe COVID-19 disease: a historical cohort study
by: Homina Saffar, et al.
Published: (2024-12-01)

Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report
by: Yuki Miyata, et al.
Published: (2025-01-01)

Emerging small-molecule antiviral agents in long COVID prevention
by: Xiaomeng He, et al.
Published: (2024-10-01)

The use of Remdesivir in pregnant women with COVID-19
by: Gulbanu Shaimerdenova, et al.
Published: (2023-02-01)

Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven
by: Richard D. Shih, et al.
Published: (2020-12-01)

Comparative therapeutic efficiency of remdesivir in COVID in a tertiary care center
by: Mahendra Munirathnam, et al.
Published: (2021-01-01)

Publicaciones sobre hidroxicloroquina y remdesivir: actualización septiembre 2020
by: Flor álvarez de Toledo
Published: (2020-10-01)

Publicaciones sobre hidroxicloroquina y remdesivir: actualización septiembre 2020
by: Flor álvarez de Toledo
Published: (2020-10-01)

Use of Remdesivir in children with COVID-19: report of an Italian multicenter study
by: Lorenza Romani, et al.
Published: (2024-02-01)

The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration’s Adverse Event Reporting System
by: Deemah S. Alsuhaibani, et al.
Published: (2023-07-01)

Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients
by: Batool Butt, et al.
Published: (2022-01-01)

Remdesivir prescription in pregnant women infected with COVID-19: A report of compassionate use
by: Azam Zafarbakhsh, et al.
Published: (2023-01-01)

Prominent bradycardia in a COVID-19 patient receiving Remdesivir: a case report
by: Sidhi Laksono Purwowiyoto, et al.
Published: (2022-07-01)

Clinical outcomes and considerations in outpatient with COVID‐19 receiving remdesivir therapy
by: Zeinab Siami, et al.
Published: (2024-07-01)

Remdesivir in a pregnant patient with COVID-19 pneumonia
by: Ranadheer Dande, et al.
Published: (2021-01-01)

Critical reappraisal of remdesivir investigational trials in COVID-19
by: P. Brouqui, et al.
Published: (2020-11-01)

Remdesivir versus standard-of-care for severe Coronavirus disease 2019 Infection: an analysis of 28-day mortality
by: Olender, Susan A., et al.
Published: (2022)

Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study
by: Abigail Schulz, et al.
Published: (2024-02-01)

Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report
by: José A Gonzales-Zamora, et al.
Published: (2020-08-01)

The journey of remdesivir: from Ebola to COVID-19
by: Joe Pardo, et al.
Published: (2020-05-01)

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
by: Alessandra D’Abramo, et al.
Published: (2021-06-01)

Measuring the energy for the molecular graphs of antiviral agents: Hydroxychloroquine, Chloroquine and Remdesivir
by: Muhammad Haroon Aftab, et al.
Published: (2024-01-01)

Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review
by: Pradeep Balasubramanian, et al.
Published: (2022-01-01)

Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections
by: S. Saqrane, et al.
Published: (2021-05-01)

Presentation of vitiligo in a case of COVID‐19 infection concomitant with receiving remdesivir
by: Farideh Beyki, et al.
Published: (2024-03-01)

Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Concetta Rafaniello, et al.
Published: (2021-06-01)

Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
by: Lakshmi Mahajan, et al.
Published: (2021-01-01)

Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics
by: Bhaswati Chatterjee, et al.
Published: (2022-05-01)

Remdesivir – Current evidence & perspective in management of COVID-19 infection
by: Jyoti Bajpai, et al.
Published: (2021-01-01)

Chitosan-Based Nanocarriers for Delivery of Remdesivir
by: Viktoria Milkova, et al.
Published: (2023-08-01)